Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?

Hologic (HOLX) reported a Q2 non-GAAP gross margin of 61.1%, a 40 bps year-over-year increase, driven by strong diagnostics sales and recent high-margin acquisitions despite a slight revenue dip. While tariffs are expected to add $20-$25 million to quarterly costs and the China revenue forecast was lowered by $20 million, Hologic anticipates full-year gross margins in the low 60s and operating margins in the low 30s, supported by growth in diagnostics, surgical, and international sales.

Analysis

Hologic demonstrated resilient profitability in its fiscal Q2 2025, achieving a non-GAAP gross margin of 61.1%, an increase of 40 basis points year-over-year, primarily driven by robust diagnostic sales and contributions from high-margin acquisitions like Endomagnetics and Gynesonics, despite a 0.5% decline in constant currency revenues. The company maintained a strong operating margin of 30%, up 60 basis points sequentially and notable within its peer group, reflecting disciplined cost management with underlying operating expenses down 4.6% when excluding acquisition impacts. However, Hologic faces significant headwinds, adopting a cautious full-year outlook due to anticipated tariff impacts of $20-$25 million quarterly to cost of goods sold, a $20 million reduction in its China revenue forecast to $50 million, and the removal of a $50 million HIV testing business from projections following the end of USAID funding. Despite these pressures, management projects full-year gross margins in the low 60s and operating margins in the low 30s, supported by expected mid-single-digit growth in Diagnostics and high-single-digit growth in Surgical. Comparatively, GE Healthcare also showed margin improvement but faces substantial tariff costs, while Bio-Rad experienced a slight gross margin decline. Hologic's stock has underperformed its industry slightly over the past six months, declining 10.4%, and trades at a premium forward price-to-sales ratio of 3.42X, with a Zacks Rank #4 (Sell) despite a projected 2.9% earnings improvement for fiscal 2025.

Key Decisions for Investors

• Investors should carefully weigh Hologic's demonstrated margin resilience and strategic acquisitions against persistent tariff pressures, a reduced China revenue outlook, and the discontinuation of its USAID-funded HIV testing business.
• Despite projected earnings growth and a strong operating margin relative to peers, the current Zacks Rank #4 (Sell) and an elevated forward P/S multiple of 3.42X warrant caution and a thorough evaluation of the risk/reward profile.
• Key factors to monitor include the realized impact of tariffs on cost of goods sold, the company's ability to achieve its guided mid-to-high single-digit growth in its Diagnostics and Surgical segments, and any further revisions to its full-year outlook amid ongoing macroeconomic volatility.